Nerviano Medical Sciences announces the publication in Science Translational Medicine of the results obtained in neuroblastoma preclinical models with a new ADC formed by the mAB KTN0125 and NMS-P945, a new proprietary thienoindole drug linker suitable for Antibody drug Conjugate (ADC) production.
Neuroblastoma is a pediatric cancer of the peripheral sympathetic nervous system that accounts for 12% of all childhood cancer mortality.
In this study, performed in collaboration with the group of Dr. Mosse at the Center for Childhood Cancer Research in Philadelphia and Celldex Therapeutics, NMS-P945 coupled with an anti-ALK antibody demonstrated anti-tumor efficacy against preclinical in vivo tumor models with relatively high cell surface ALK expression. This approach should also be uniquely safe due to the absence of ALK expression on normal tissues and the obtained data support the rationale for future clinical development of an ALK-ADC approach for neuroblastomas and other ALK-expressing childhood cancers. Preliminary data were presented at the 2016 AACR held in New Orleans; now the completed study published in the prestigious Science Translational Medicine represents the first peer reviewed article concerning NMS-P945.
An antibody-drug conjugate directed to the ALK receptor demonstrates efficacy in preclinical models of neuroblastoma. Renata Sano1, Kateryna Krytska1, Colleen E. Larmour1, Pichai Raman2, Daniel Martinez3, Gwenda F. Ligon4, Jay S. Lillquist4, Ulisse Cucchi5, Paolo Orsini5, Simona Rizzi5, Bruce R. Pawel3, Diego Alvarado4, Yael P. Mossé1,6*, Science Translational Medicine 13 Mar 2019: Vol. 11, Issue 483.